Hu Yin-Bao, Duan Lei, Liu Guang-Yu, Wang Xiao-Ming
Department of Gastroenterology, Panzhihua Central Hospital, Panzhihua, Sichuan Province, 617067, China.
BMC Surg. 2025 Jul 3;25(1):270. doi: 10.1186/s12893-025-03028-y.
Volume measurement software is not routinely utilized in clinical practice before splenic artery embolization. To explore the function of such software measurement in this context, we conducted a retrospective study.
We divided patients into two groups: 38 patients in Group A underwent three-dimensional reconstruction using Revolution CT, and 37 patients in Group B underwent imaging with normal CT technology. We compared the changes in liver function test results and haematological parameters between these two groups.
A total of 75 patients who underwent splenic artery embolization from January 2018 to January 2023 were included. The preoperative baseline data were not significantly different (all P values > 0.05). Both groups showed improvements in liver function and hypersplenism-related parameters. Within 2 weeks after surgery, Group A had significantly greater WBC (5.54 ± 1.92 × 10^9/L) and PLT (65.80 ± 20.12 × 10^9/L) counts than Group B (WBC: 4.14 ± 1.96 × 10^9/L; PLT: 52.70 ± 14.78 × 10^9/L; P < 0.05), indicating better control of hypersplenism. At 2 months postintervention, Group A demonstrated more favourable improvements in postintervention splenic volume (reduced from 1045 ± 122.9 cm³ to 489.5 ± 84.93 cm³), portal vein diameter (from 1.51 ± 0.19 cm to 1.28 ± 0.13 cm), and portal vein flow velocity (increased from 17.70 ± 5.25 cm/s to 23.56 ± 6.40 cm/s) than Group B. Moreover, a 53.2% splenic volume reduction was noted in Group A, which was significantly greater than the 31.4% reduction in Group B. Additionally, Group A had fewer adverse reactions, with lower liver/gastrointestinal toxicity (χ²=4.242, P = 0.039) and fever severity (χ²= 4.805, P = 0.028).
This study suggests that using Revolution CT prior to splenic artery embolization provides an effective method for managing hypersplenism, enhancing liver function, and reducing the risk of complications.
在脾动脉栓塞术之前,容积测量软件在临床实践中并未得到常规应用。为了探索此类软件测量在此背景下的作用,我们进行了一项回顾性研究。
我们将患者分为两组:A组38例患者使用Revolution CT进行三维重建,B组37例患者采用普通CT技术进行成像。我们比较了两组患者肝功能检查结果和血液学参数的变化。
纳入了2018年1月至2023年1月期间共75例行脾动脉栓塞术的患者。术前基线数据无显著差异(所有P值>0.05)。两组患者的肝功能和脾功能亢进相关参数均有所改善。术后2周内,A组的白细胞计数(5.54±1.92×10^9/L)和血小板计数(65.80±20.12×10^9/L)显著高于B组(白细胞:4.14±1.96×10^9/L;血小板:52.70±14.78×10^9/L;P<0.05),表明对脾功能亢进的控制更好。干预后2个月,A组在干预后的脾体积(从1045±122.9 cm³降至489.5±84.93 cm³)、门静脉直径(从1.51±0.19 cm降至1.28±0.13 cm)和门静脉流速(从17.70±5.25 cm/s增至23.56±6.40 cm/s)方面的改善比B组更显著。此外,A组的脾体积缩小了53.2%,显著大于B组的31.4%。此外,A组的不良反应较少,肝/胃肠道毒性较低(χ²=4.242,P=0.039),发热严重程度较低(χ²=4.805,P=0.028)。
本研究表明,在脾动脉栓塞术之前使用Revolution CT是一种有效管理脾功能亢进、改善肝功能和降低并发症风险的方法。